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Summary 
Background: Ebola virus disease (EVD) is caused by Ebola viruses (EBOV), members of the group of 
hemorrhagic fevers and it is one of the most dangerous infection diseases with mortality rates up to 90%. Ebola 
was firstly described in 1976 and since then occurred sporadically in Central Africa. Till 2014, twenty four 
outbreaks were described, but the number of deaths not exceeding 300 per outbreak. As of May 20, 2015 the 
cumulative number, suspected, and laboratory-confirmed cases attributed to Ebola virus was 26, 969, including 
11,135 deaths. 
 Pathogenesis: Ebola Viruses do not replicate through cell division, but instead insert their own genetic 
sequencing into the deoxyribonucleic acid (DNA) of the host cell and subsequently hijack all cellular processes, 
including transcription and translation. In essence, the host cell becomes a factory of viral proteins. As new viral 
capsules are formed, they bud from the host cell, taking a part of the host cell’s outer membrane, thus cloaking 
themselves against detection by the host’s immune system. In some cases, the patient’s immune system can 
produce enough antibodies to defeat the infection. With EVD, the virus can often reproduce so rapidly that the 
immune system never catches up.  
Transmission: The natural reservoir of EBOV is believed to be bats, particularly  fruit  bats,  and  it  is  
primarily  transmitted  between  humans  and  from  animals  to humans  through  body  fluids. 
Clinical presentation: Symptoms  of  EVD include  abrupt  onset  of  fever, myalgias,  and  headache  in  the  
early  phase,  followed  by  vomiting,  diarrhea  and possible  progression  to  hemorrhagic  rash,  life-threatening  
bleeding,  and  multi organ failure in the later phase.  
Treatment: There are no approved treatments or vaccines available for EVD until today; the mainstay of 
therapy is supportive care.  However, there are a bunch of therapeutic approaches on the track which could have 
the real impact on control and prevention of this global threat.  High fatality, combined with the absence of 
treatment and vaccination options, makes Ebola virus an important public health pathogen and biothreat 
pathogen of category A.  
Keywords: Ebola virus, Ebola virus disease, hemorrhagic fever, outbreak, epidemic, supportive care, reservoir, 
West Africa. 
 
INTRODUCTION 
Background 
Ebola virus disease (formerly called Ebola Hemorrhagic Fever) is a severe, often fatal, disease in humans and 
nonhuman primates, which is caused by the Ebola virus. Between 1976 and 2014 twenty-four epidemics of 
Ebola virus disease (EVD) were verified, mostly caused by Zaire Ebola virus (ZEBOV) in Equatorial Africa. 
Most outbreaks have been small, but the virus captured the attention of the world due to death rates that can be 
as high as 90% as well as the visceral manner in which it kills [1- 3]. 
In March 2014, World Health Organization (WHO) reported a major Ebola outbreak in Guinea, Liberia 
and Sierra Leone, western African nations. The 2014 EVD outbreak in West Africa caused by ZEBOV is the 
longest, largest, deadliest, and the most complex in history. As of 11 February 2015, there were 22,859 EVD 
cases and a total of 9,162 deaths. Compared to the cumulative sum of past episodes in 36 years (1976-2012), 
2,232 infected people and 1,503 deaths there are now over ten times the total number infection cases and over six 
times the total number of fatalities [1,4,5]. The Ebola virus disease outbreak in West Africa affected 
impoverished post-conflict countries with weak health systems and no experience with Ebola. [6]. 
Ebola is a public health nightmare because it can be contacted relatively easily (especially in a hospital 
setting where proper precautions are not taken) and is almost always fatal. EVD can be transmitted between 
humans through direct contact with bodily fluids (e.g., blood, sweat) from an infected person or contaminated 
objects. Whereas aerosol infection has not been reported clinically, despite it has been demonstrated in 
experimental infection in monkeys [7, 8]. One  of  the  reasons  that  Ebola  is  so  dangerous  that  its symptoms 
are varied and appear quickly, yet resemble those of other viruses so much that the hemorrhagic  fever is not 
rapidly diagnosed [2]. The current outbreak gives an opportunity to evaluate vaccine efficacy, safety and there is 
an acute need for a vaccine [9]. 
Most studies recommended that, the best chance for survival once infected is early diagnosis followed 
by comprehensive supportive care. While diagnostic tests exist, they often result in false negatives in those who 
have recently begun to experience symptoms, so isolation and retesting is often the best course of action. [10].  
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Classification  
Ebola virus, formerly designated Zaire Ebola virus is one of five known viruses within the genus Ebola virus, 
family filoviridae, and order mononegavirales [11, 12]. 
Filovirus outbreak is one of the most fatal  viral  diseases  worldwide  affecting  humans and nonhuman primates 
(NHPs) and therefore, EBOV  is identified  as a bio-safety level 4 pathogens and CDC category A agents of  
bioterrorism [13].  
 
                                                  Figure1: Taxonomy of Filovirus          
Outbreak of Ebola virus disease 
Table I: Ebola outbreaks between 1976 and 2014, adapted from WHO [14]  
Year Country, 
Village 
EboV 
subtype 
Number 
of 
human 
cases 
Number 
of deaths  
Mortality Source and spread of infection 
 
1976 
Sudan, Nzara 
and Marida 
Sudan virus  
284 
 
151 
 
53% 
Spread by close contact within hospitals, 
many hospital staff were infected 
 
1976 
Zaire, 
Yambuku 
Ebola virus  
318 
 
280 
 
88% 
Contaminated needles and syringes in 
hospitals 
 
1976 
 
England 
Sudan virus  
1 
 
0 
 Laboratory infection, accident-stick of 
contaminated needles 
 
1977 
Zaire, 
Tandala 
Sudan virus  
1 
 
1 
 
100% 
 
Noted retrospectively 
 
1979 
Sudan, Nzara 
and Marida 
Sudan virus  
34 
 
22 
 
65% 
Recurrent outbreak at the same site as the 
1976 
 
1989 
USA, 
Viriginia 
and 
Pennsylvania 
 
Restone 
virus 
 
0 
 
0 
 EboV was introduced in to quarantine 
facility by monkeys from the Philippines 
1989-
1990 
 
Philippines 
Restone 
virus 
 
3 
 
0 
 Source: macaques from USA. Three 
workers (animal facility) developed 
antibodies, did not get sick 
 
1990 
 
USA, Viriginia 
Restone 
virus 
 
4 
 
0 
  
The same to 1989 
 
1994  
 
Gabon 
Ebola virus  
52 
 
31 
 
60% 
Initially thought to be yellow fever, 
identified as Ebola in 1995 
 
1994 
 
Cote d’Ivoire 
Tai Forest 
virus 
 
1 
 
0 
  
Scientist become ill after autopsy on a 
wild chimpanzee (Tai Forest) 
 Democratic Ebola virus    Case-patient worked in the forest, spread 
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1995 Republic of 
Congo(Zaire 
315 250 81% through families and hospitals 
 
1996 
 
Gabon 
Ebola virus  
37 
 
21 
 
57% 
Chimpanzee found dead in the forest was 
eaten by hunters, spread in family 
members 
1996-
1997 
 
Gabon 
Ebola virus  
60 
 
45 
 
74% 
Case-patient was a hunter from forest 
camp, spread by cloth contact 
 
1996 
 
South Africa 
Ebola virus  
2 
 
1 
 
50% 
Infected medical professional traveled 
 
1996 
 
Russia 
Ebola virus  
1 
 
1 
 
100% 
 
Laboratory contamination 
 
2000- 
2001 
 
 
Uganda 
 
Sudan virus 
 
 
425 
 
 
224 
 
 
53% 
Providing medical care to Ebola case-
patient without using adequate personal 
protective measures 
2001-
2002 
 
Gabon 
Ebola virus  
65 
 
53 
 
82% 
Outbreak occurred over border of Gabon 
and Republic of Congo 
2001-
2002 
Republic of the 
Congo 
Ebola virus  
57 
 
43 
 
75% 
Outbreak occurred over border of Gabon 
and Republic of the Congo 
2002-
2003 
 
Republic of the 
Congo 
 
Ebola virus 
 
 
143 
 
 
128 
 
 
89% 
Outbreak in the districts of Mbomo and 
kelle in Cuvette Ouest Department 
 
2003 
Republic of the 
Congo 
Ebola virus  
35 
 
29 
 
83% 
Outbreak in villages located in Mbomo 
district, Cuvette Ouest Department 
 
 
 
2004 
 
 
Sudan, 
Yambio 
 
 
Sudan 
Virus 
 
 
 
17 
 
 
 
7 
 
 
 
41% 
Outbreak concurrent with an outbreak of 
measles, and several cases were later 
reclassified as measles 
 
2004 
 
Russia 
Ebola virus  
1 
 
1 
 
100% 
 
Laboratory infection 
 
2007 
Democratc 
republic of the 
Congo 
Ebola virus  
264 
 
187 
 
71% 
The outbreak was declared over 
November 20. Last death on October 10 
2007-
2008 
Uganda Bundibugyo 
virus 
 
149 
 
37 
 
25% 
First reported occurrence of a new strain 
 
2008 
 
Philippines 
Reston 
virus 
 
6 
 
0% 
 Six workers (pig farm) developed 
antibodies, did not become ill 
2008-
2009 
Democratic 
republic of the 
Congo 
Ebola virus  
32 
 
15 
 
47% 
 
Not well identified 
 
2011 
 
Uganda 
 
Sudan 
Virus 
 
1 
 
1 
 
100% 
The Uganda Ministry of Health informed 
the public a patient with suspected Ebola 
died on May 6, 2011 
 
2012 
Uganda, 
Kibaale 
Sudan 
Virus 
 
11 
 
4 
 
36% 
Laboratory tests of blood samples were 
conducted by the UVRI and the CDC 
 
2012 
Democratic 
republic of the 
Congo 
Bundibugyo 
virus 
 
36 
 
13 
 
36% 
This outbreak had no link to the 
contemporaneous Ebola outbreak in the 
kibaale, Uganda 
2012-
2013 
Uganda Sudan virus  
6 
 
3 
 
50% 
CDC assisted the ministry of Health in 
the epidemiology and diagnosis of the 
outbreak 
 
2014 
Democratic 
republic of the 
Congo 
Zaire virus  
66 
 
49 
 
74% 
The outbreak was unrelated to the 
outbreak of West Africa 
 
West Africa Outbreaks  
Table II: Ebola Virus Disease cases West Africa outbreak at 12/4/15 [15 ]                        
Country All cases 
                                             
Health care workers 
Cases Deaths Cases                              Deaths 
Guinea 3548 2346 187 94 
Sierra Leone 12,206 3857 303 221 
Liberia 10,042 4486 374 188 
Total 25,791 10,689 864 503 
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Virology and Pathogenesis  
The genome of Ebola virus is 18,959 nucleotides in length and 80 nanometers (nm) in width containing only 
seven Open Reading Frames (ORFs). Despite limited encoding capacity, this virus expands its gene functions by 
forming more proteins and assigning more functions to each of them. Nine proteins have been known to be 
translated, including nucleoprotein (NP), the polymerase cofactor viral protein (VP35), the major matrix protein 
(VP40), glycoprotein (GP), soluble glycoprotein (sGP), small soluble glycoprotein (ssGP), transcription activator 
(VP30), the minor matrix protein (VP24), and viral RNA-dependent RNA polymerase (L). The GP, a surface 
protein inserted into the viral membrane, functions during virus entry into the host cells by binding to its receptor 
and fusion with cell membrane [16]. 
Viral genes including 3’-UTR (un translated regions)-NP-VP35-VP40-GP-VP30-VP24-L-5’-UTR, that 
are transcribed by the viral RNA dependent RNA Polymerase present in the virion. The single strand of RNA is 
covered by helically arranged viral nucleoproteins NP and VP30, which are linked by matrix proteins VP24 and 
VP40 to the lipid bilayer that coats the virion [17]. Viral protein 35 (VP35), encoded by filoviruses, is a 
multifunctional dsRNA binding protein that plays important roles in viral replication, innate immune evasion, 
and pathogenesis. The multifunctional nature of these proteins also presents opportunities to develop 
countermeasures that target distinct functional regions. The EBOV matrix protein is VP40, which is also found 
localized under the lipid envelope of the virus where it bridges the viral lipid envelope and nucleocapsid. The 
VP40 is effectively a peripheral protein that mediates the plasma membrane binding and budding of the virus 
prior to egress. The Ebola virus structural glycoprotein (known as GP 1, 2) is responsible for the virus’ ability to 
bind to and infect targeted cells. The viral RNA polymerase encoded by the L gene, partially uncoated the 
nucleocapsid and transcribes the genes into positive-strand mRNAs, which are then translated into structural and 
nonstructural proteins [13, 16].  
 
Pathogenesis 
The path physiology of Ebola is not yet fully understood, however, most studies report that the incubation period 
varies depending on the type of exposure (i.e., six days for percutaneous and ten days for contact exposure). The 
WHO Ebola response team’s findings have documented that the mean incubation period was 11.4 days, which 
did not vary by country. Following viral transmission, symptoms usually appear in approximately eight to ten 
days (range, 2-21 days). Because of the difficulty of performing clinical studies under outbreak conditions, 
almost all data on the pathogenesis of Ebola virus disease have been obtained from laboratory experiments 
employing mice, guinea pigs, and nonhuman primates. However, case reports and large-scale observational 
studies of patients in the 2014-2015 West Africa outbreaks are providing urgently needed data on the 
pathogenesis of the disease in humans [18, 19]. 
 
Figure 2: Diagram demonstrating the pathogenesis of Ebola virus infection.  
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Phase I can be characterized as the transfer of EBOV from an animal carrying the virus to a human, usually via 
small cutaneous lesions. Similar principles apply in human-to-human transmission during Ebola outbreaks. 
Phase II can be characterized as the early symptomatic stage - usually between days four and ten - where 
symptoms of a viral illness appear and gradually progress toward more advanced manifestations of the disease. 
Finally, Phase III represents the advanced Ebola virus disease, with hemorrhagic manifestations, impaired 
immunity, and end-organ failure. Adapted from Journal of Global Infectious Diseases/ Oct-Dec 2014 / Vol-6 
/Issue-4. NHP = nonhuman primate; TNF = Tumor necrosis factor; IL = Interleukin 
 
Cell entry and tissue damage 
After entering the body through mucous membranes, breaks in the skin, or parentally, Ebola virus infects many 
different cell types. Macrophages and dendrite cells are probably the first to be infected; filoviruses replicate 
readily within these ubiquitous’’ sentinel’’ cells, causing their necrosis and releasing large numbers of new viral 
particles into extracellular fluid [13, 20]. Rapid systemic spread is aided by virus-induced suppression of type l 
interferon responses. Dissemination to regional lymph nodes results in further rounds of replication, followed by 
spread through the bloodstream to dendrite cells and fixed and mobile macrophages in the liver, spleen, thymus, 
and other lymphoid tissues. Necropsies of infected animals have shown that many cell types (except for 
lymphocytes and neurons) may be infected, including endothelial cells, fibroblasts, hepatocytes, adrenal cortical 
cells, and epithelial cells. Fatal infection is characterized by multifocal necrosis in tissues such as the liver and 
spleen [21]. And resulted Impairment of adaptive immunity, Coagulation defect, Systemic inflammatory 
response, gastrointestinal dysfunction 
 
Viral Reservoirs and Mode of Transmission  
Viral reservoirs 
The natural reservoir for Ebola has not identified until today; however, bats are considered to the most likely 
candidate species. Three types of fruit bats (Hypsignathus monstrous, Epomops franqueti and Myonycteris 
torquata) were found to possibly carry the virus without getting sick [2]. Bats were known to roots in the cotton 
factory in which the first cases of the 1976 and 1979 outbreaks were observed, and they have also been 
implicated in Marburg virus infection in 1975 and 1980.  Of 24 plant and 19 vertebrate species experimentally 
inoculated with EBOV, only bats displayed no clinical signs of disease, which is considered evidence that these 
bats are a reservoirs species of EBOV. In a 2002 -2003 survey of 1,030 animals including 679 bats from Gabon 
and the Republic of the Congo, 13 fruit bats were found to contain EBOV RNA.  
 
Figure 3: Fruit eating bat: Natural host for Ebola virus disease 
 
Mode of Transmission  
Epidemics of Ebola virus disease are generally through to begin when an individual becomes infected through 
contact with the meat or body fluids of an infected animal. Once the patient becomes ill or dies, the virus then 
spreads to others who come into direct contact with the infected individual’s blood, skin or other body fluids. 
Studies in laboratory primates have found that animals can be infected with Ebola virus through droplet 
inoculation of virus into the animal mouth or eyes suggesting that human infection can result from the 
inadvertent transfer of virus to these sites from contaminated hands [22, 23]. 
Person-to-person transmission occurs through direct contact with blood, body fluids, or skin of patients 
with Ebola virus disease, including those who have died from the infection.  Kissing the body is also common. 
These practices can be extremely dangerous because Ebola victims are often most contagious just after death, 
when the viral load in their blood is at its highest [10, 24]. 
According to the WHO, the most infectious body fluids are blood, feces, and vomit. Infectious virus has 
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also been detected in urine, semen, saliva, and breast milk [25, 26]. Ebola virus can also be spread through direct 
contact with the skin of patient, but the risk of developing infection from this type of exposure is lower than from 
exposure to body fluids [27]. 
A number of studies examining airborne transmission broadly concluded that transmission from pigs to 
primates could happen without direct contact, because pigs with EVD get very high Ebola virus concentrations 
in their lungs, and not their bloodstream. Therefore pigs with EVD can spread the disease through droplets in the 
air or on the ground when they sneeze or cough. By contrast, humans and other primates accumulate the virus 
throughout their body and specifically in their blood, but not very much in their lungs [2].  
Human infection with Ebola virus can occur through contact with wild animals such as hunting, 
butchering, and preparing meat from infected animals [4].   
 
Clinical Presentation and Diagnosis 
Clinical Presentation 
The incubation period and duration of the disease course of Ebola virus disease varies between 2-21 days with an 
average of 4-10 days [16]. 
 
Symptoms  
Symptoms usually begin with a sudden flu-like symptoms like quickly on-coming fever, mayopathy, and 
headache, which are soon followed by bloody vomit and diarrhea, nausea and vomiting, anorexia (loss of 
appetite), body weakness, abdominal pain, arthralgia (neurologic pain in joints), back pain, mucosal redness of 
the oral cavity, dysphasia (difficult in swallowing), conjunctivitis, rashes on the body [3]. Some days later, 
typically begins five to seven days after the first symptoms victims can begin to bleed through the eyes, nose, or 
mouth. A hemorrhagic rash can develop on the entire body, which also bleeds. Muscle pain and swelling of the 
pharynx also occur in most victims. The most common signs and symptoms reported from West Africa during 
the current outbreak from symptom-onset to the time the case was detected include: fever(87%), fatigue (76%), 
vomiting (68%),diarrhea (66%), and loss of appetite (65%). Unexplained bleeding has been reported from only 
18% of patients, most often blood in the stool (about 6%) [13].  
 
Figure 4. Bleeding of blood from throughout the body is the characteristic symptoms of Ebola-Virus    
Diagnosis and differential diagnosis 
When Ebola virus disease is suspected in person, his or her travel and work history, along with an exposure to 
wildlife, are important factors to consider with respect to further diagnostic efforts. 
 
Nonspecific laboratory testing  
Possible laboratory indicators of Ebola virus disease include a low platelet count; an initially decreased white 
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blood cell count followed by an increased white blood cell count; elevated levels of the liver enzymes alanine-
aminotransferase (ALT) and aspartate aminotransferase (AST); and abnormalities in blood clotting often 
consistent with disseminated intravascular coagulation (DIC) such as a prolonged prothrombin time, partial 
thromboplastin time, and bleeding time [2]. 
 
Specific laboratory testing  
The diagnosis of EVD is confirmed by isolating the virus, detecting antibodies against the virus in a person’s 
blood. Isolating the virus by cell culture, detecting the viral RNA by polymerase chain reaction (PCR) and 
detecting proteins by enzyme-linked immunosorbent assay (ELISA) are methods best used in early stages of the 
disease and also for detecting the virus in human remains. Detecting antibodies against the virus is most reliable 
in later stages of the disease and in those who recover. IgM antibodies are detectable two days after symptom 
onset and IgG antibodies can be detected 6 to18 days after symptom onset [28]. 
 Table III. Most important para clinical findings in the course of Ebola virus disease 
Hemoglobin & Hematocrit Progressive decline(with hemorrhage) 
 
White blood cells 
Early leucopenia with lymphopenia and subsequent neutrophilia, left shift 
with atypical lymphocytes, in fatal cases leuocytosis 
Platelets Thrombocytopenia 
 
Liver-associated enzymes 
Highly raised serum aminotransferase (aspartate aminotranferase), 
hyperproteinaemia 
Renal functions Hematuria, proteinuria,  
 
 
Coagulations 
Prolongation of prothrombine and partial thromboplastin time and fibrin split 
produce are detectable 
Other serum chemistry values Serum amylase concentration may be raised 
 
Differential diagnosis 
Early symptoms may resemble other tropical infectious diseases like influenza, malaria, typhoid fever, 
leptospirosis, relapsing fever, anthrax, typhus, non typhoidal salmonellosis, Dengue fever, Chikungunya fever, 
yellow fever, Lassa fever, Marburg fever, fulminant viral hepatitis, meningococcal septicemia and various forms 
of encephalitis, which are also prevalent in these countries. Confounding noninfectious syndromes with 
hemorrhage such as acute leukemia, lupus erythematous, idiopathic thrombocytopenic purpura, and hemolytic 
uremic syndrome also fall into the differential diagnosis [16]. 
 
Prevention and Treatment 
Prevention 
General approach   
People who care for those infected with Ebola should wear protective clothing including masks, gloves, gowns 
and goggles. In 2014, the CDC began recommending that medical personal protective equipment (PPE); in 
addition, a designated person, appropriately trained in biosafety, should be watching each step of these 
procedures to ensure they are done correctly. [2]. 
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Figure 5. A pictorial representation of protective equipment used by health care personnel for Ebola virus disease.  
Journal of Global Infectious Diseases / Oct-Dec 2014 / Vol-6 / Issue-4). 
Several concurrent strategies should be employed to prevent the spread of Ebola virus. Strict infection 
control measures and the proper use of personal protective equipment are essential to prevent transmission to 
healthcare workers. In addition, individuals who have been exposed to Ebola virus should be monitored, so that 
they can be identified quickly if signs and symptoms develop. During the 2014 outbreak, kits were put together 
to help families treat Ebola disease in their homes, which include protective clothing as well as chlorine powder 
and other cleaning supplies. Education of those who provide care in these techniques, and the provision of such 
barrier-separation supplies has been a priority of Doctors without Borders. Ebola virus can be eliminated with 
heat (heating for 30 to 60 minutes at 60 °C or boiling for 5 minutes). To disinfect surfaces, some lipid solvents 
such as some alcohol-based products, detergents, sodium-hypochlorite (bleach) or calcium hypochlorite 
(bleaching powder), and other suitable disinfectants may be used at appropriate concentrations [22,29,30]. 
Bus meat, an important source of protein in the diet of some Africans, should be handled and prepared 
with appropriate protective clothing and thoroughly cooked before consumption. If a person with Ebola disease 
dies, direct contact with the body should be avoided. Certain burial rituals, which may have included making 
various direct contacts with a dead body, require reformulation such that they consistently maintain a proper 
protective barrier between the dead body and the laving [31]. 
Contact tracing is considering important to contain an outbreak. If any of these contacts comes down 
with the disease, they should be isolated, tested and treated. Then the process is repeated by tracing the contacts’ 
contacts [32]. 
 
Isolation and Quarantine 
Isolation refers to separating those who are sick from those who are not. Quarantine refers to separating those 
who may have been exposed to a disease until they either show signs of the disease or are no longer at risk. In 
the United States, the law allows quarantine of those infected with Ebola virus. During the 2014 Ebola disease 
outbreak, Liberia closed schools [33,34]. 
 
Environmental infection control 
If a patient with suspected or confirmed Ebola virus disease is being cared for in a healthcare setting, specific 
precautions should be taken to reduce the potential risk of virus transmission through contact with contaminated 
surfaces. The CDC has provided specific recommendations for environmental infection control in hospitals, 
general healthcare settings in West Africa, and provides information about restrictions on travel and transport of 
asymptomatic persons who have been exposed to Ebola virus. Asymptomatic persons who have had a possible 
exposure at any risk level should be monitored for signs and symptoms of Ebola virus disease. Monitoring 
should continue for 21 days after the last known exposure; the development of fever and/or other clinical 
manifestations suggestive of Ebola virus disease should be reported immediately [22]. 
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Breastfeeding and infant care 
Ebola virus can be transmitted by close contact of an infected mother with her children. Thus, the CDC 
recommends that mothers with Ebola virus disease avoid close contact with their infants if the infant can receive 
adequate care and nutrition in other ways [35, 36]. 
 
Precautions during the convalescent period 
Patients recovering from Ebola virus disease may continue to have virus present in certain body fluids (e.g. urine, 
semen, vaginal secretions, and breast-milk) even if virus is no longer detectable in the blood. However, the risk 
of transmission secondary to virus in these sites remains unclear.  To prevent sexual transmission of Ebola 
through semen, the WHO recommends that men abstain from sex (including oral sex) for three months after 
onset of symptoms, or use condoms if abstinence is not possible. There are currently no recommendations to 
guide when infected women can resume sexual activity and /or breast feeding [37]. 
 
Pregnancy 
The CDC and the American College of Obstetrics and Gynecology have issued recommendations for the care of 
pregnant women with Ebola virus disease. Strict infection control precautions must be used when caring for all 
pregnant patients with Ebola virus disease. Case reports suggest that there is a high risk for fetal death and 
pregnancy-associated hemorrhage. However, there are no data to suggest whether cesarean or vaginal delivery is 
preferred or when the baby should be delivered. [38]. 
 
Vaccines 
Due to the pathogencity of the virus, no conventional vaccines consisting of inactivated/killed virus, or made 
from an attenuated viral strain, are being developed for Ebola because of the risk of incomplete inactivation of 
the virus or of reversion to a fully active form. Instead, these vaccines are based on relatively new approaches 
that have been made possible with the advancement of  molecular  biology  and  recombinant  genetic  
technologies introduced  during  the  last  10-20  years.  Clinical trials for several candidate vaccines are in 
various phases and a safe and effective vaccine is hoped for by the end of 2015. Currently, two vaccine 
candidates are entering efficacy trials in humans [39, 40].   
The first is cAd3-ZEBOV developed by GlaxoSmithKline and tested by the US National Institute of 
Allergy and Infectious Diseases (NIAID). The second is the rVSV tested by the New Link Genetics Corporation 
after being licensed from the Public Health Agency of Canada. Both vaccines demonstrated promising rates of 
efficacy in nonhuman primates, but the translation of these results to human subjects has not yet been 
accomplished [40, 41]. 
 
Treatment 
Approach to therapy 
There are no approved treatments available for EVD. Clinical management should focus on supportive care of 
complications, such as hypovolemia, electrolyte abnormalities, hematologic abnormalities, refractory shock, 
hypoxia, hemorrhage, septic shock, multi-organ failure. The mainstay of treatment for Ebola virus disease 
involves supportive care to maintain adequate cardiovascular function while the immune system mobilizes an 
adaptive response to eliminate the infection. In addition, several experimental antiviral therapies have been used 
in patients with Ebola virus disease during the 2014 outbreak in West Africa. The efficacy of these agents is 
unclear and is an active area of investigation. In addition, the availability of these drugs is limited [13, 17]. 
 
Antiviral therapy  
There are no approved medications for the treatment of Ebola virus disease or for post-exposure prophylaxis in 
persons who have been exposed to the virus but have not yet become ill. There is urgent need for evaluation of 
several experimental therapies that had been developed  specifically to treat or prevent Ebola or Marburg virus 
infection, but have only been tested in laboratory animals .In addition, there is renewed interest in the potential 
value of convalescent plasma and whole blood transfusions from  Ebola survivors.  Although experimental 
treatments for Ebola virus infection are under development, they have not yet been fully tested for safety or 
effectiveness [42].  
Non-clinical and clinical data made available for:  
      • Three nucleoside polymerase inhibitors: BCX4430, brincidofovir, and favipiravir; 
      • Two oligonucleotide based products: TKM-100802 and AVI-7537; 
      • A cocktail of monoclonal antibodies: ZMapp 
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List of Acronyms 
ALT       Alanine Aminotransferase 
AST       Aspartate Aminotransferase 
BDBV    Bundibugyo Ebola virus 
CDC       Center for Disease and Prevention  
DIC        Disseminated Intravascular Coagulation 
DNA      Deoxyribonucleic acid 
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EBOV     Ebola virus 
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US           United state  
WAEO    West Africa Ebola Outbreak  
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